CYP19A1 and breast cancer: The results of a high-throughput study screening of 7000 compounds identified an imidazolyl quinoline derivative of flavonoids with aromatase inhibitor effect at a concentration of 0.81 μM decreasing the proliferation of T47D breast cancer cells [66].